This roundtable series assists in the evaluation of multiple lines of therapies for patients with metastatic breast cancer as discussed by participants at virtual live events.
Part 2: Experiences With Sacituzumab and Biomarkers for TNBC
December 31st 2021During a live virtual event, Joyce O'Shaughnessy, MD, discussed participants' experiences with the tolerability of sacituzumab govitecan in patients with metastatic triple-negative breast cancer. The participants also discussed their approaches to molecular testing for biomarkers at the time of disease relapse or progression.
POLL: What Treatment Would You Choose for BRCA-, PD-L1- Metastatic TNBC?
April 25th 2022Participants of a live, virtual case-based event discussed different scenarios for treatment of a patient with BRCA and PD-L1 negative, metastatic triple-negative breast cancer. Vote in the polls on what you would have chosen if this was your patient.
Selecting Frontline Therapy for TNBC After Progression on Adjuvant Therapy
July 22nd 2022During a Targeted Oncology case-based roundtable event, Elizabeth Ann Mittendorf, MD, discussed with participants their choice of treatment after progression for a patient with triple-negative breast cancer treated with adjuvant dose-dense doxorubicin plus cyclophosphamide with paclitaxel. This is the first of 2 articles based on this event.
Exploring Sacituzumab Govitecan and Other Second-Line TNBC Therapies
August 15th 2022During a live virtual event, Elizabeth Ann Mittendorf, MD, PhD, discussed the case of a patient with triple-negative breast cancer whose disease progressed following adjuvant dose-dense doxorubicin plus cyclophosphamide with paclitaxel, then frontline gemcitabine and carboplatin. This is the second of 2 articles based on this live event.
Managing Adverse Events of Sacituzumab Govitecan in TNBC
February 20th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Hope S. Rugo, MD, discussed with participants the management of neutropenia and other toxicities associated with the antibody-drug conjugate sacituzumab govitecan in patients with metastatic triple-negative breast cancer.
Managing Sacituzumab AEs and Looking Forward to Next-Line TNBC Therapy
March 6th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Hope S. Rugo, MD, discussed adverse event management in patients treated with sacituzumab govitecan for triple-negative breast cancer and other therapy options. This is the second of 2 articles based on this event.
Favorable Toxicity Management with Sacituzumab Govitecan in Advanced Breast Cancer
November 6th 2023In the second article of a 2-part series, Aditya Bardia, MD, MPH, discusses the favorable toxicity profile of sacituzumab govitecan for patients with metastatic breast cancer and how he handles neutropenia through the course of treatment.